BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18694848)

  • 21. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
    Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
    Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a quantitative biochemical and cellular sphingomyelin synthase assay using mass spectrometry.
    Chen Y; Yurek DA; Yu L; Wang H; Ehsani ME; Qian YW; Konrad RJ; Jiang XC; Kuo MS; Cao G; Wang J
    Anal Biochem; 2013 Jul; 438(1):61-6. PubMed ID: 23535273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of the selective sphingomyelin synthase 2 inhibitors with the novel structure of oxazolopyridine.
    Qi XY; Cao Y; Li YL; Mo MG; Zhou L; Ye DY
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3511-3515. PubMed ID: 28619536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingomyelin Synthase Family and Phospholipase Cs.
    Jiang XC; Chiang YP
    Adv Exp Med Biol; 2022; 1372():77-86. PubMed ID: 35503176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage.
    Separovic D; Semaan L; Tarca AL; Awad Maitah MY; Hanada K; Bielawski J; Villani M; Luberto C
    Exp Cell Res; 2008 May; 314(8):1860-8. PubMed ID: 18374917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death.
    Lafont E; Milhas D; Carpentier S; Garcia V; Jin ZX; Umehara H; Okazaki T; Schulze-Osthoff K; Levade T; Benoist H; Ségui B
    Cell Death Differ; 2010 Apr; 17(4):642-54. PubMed ID: 19779494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene.
    Burns TA; Subathra M; Signorelli P; Choi Y; Yang X; Wang Y; Villani M; Bhalla K; Zhou D; Luberto C
    J Lipid Res; 2013 Mar; 54(3):794-805. PubMed ID: 23160178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors.
    Li YL; Qi XY; Jiang H; Deng XD; Dong YP; Ding TB; Zhou L; Men P; Chu Y; Wang RX; Jiang XC; Ye DY
    Bioorg Med Chem; 2015 Sep; 23(18):6173-84. PubMed ID: 26314925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER.
    Vacaru AM; Tafesse FG; Ternes P; Kondylis V; Hermansson M; Brouwers JF; Somerharju P; Rabouille C; Holthuis JC
    J Cell Biol; 2009 Jun; 185(6):1013-27. PubMed ID: 19506037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
    Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
    J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
    Adachi R; Ogawa K; Matsumoto SI; Satou T; Tanaka Y; Sakamoto J; Nakahata T; Okamoto R; Kamaura M; Kawamoto T
    Eur J Med Chem; 2017 Aug; 136():283-293. PubMed ID: 28505533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of membrane KCNQ1/KCNE1 channel density by sphingomyelin synthase 1.
    Wu M; Takemoto M; Taniguchi M; Takumi T; Okazaki T; Song WJ
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C15-23. PubMed ID: 27194473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential localization of sphingomyelin synthase isoforms in neurons regulates sphingomyelin cluster formation.
    Kidani Y; Ohshima K; Sakai H; Kohno T; Baba A; Hattori M
    Biochem Biophys Res Commun; 2012 Jan; 417(3):1014-7. PubMed ID: 22209789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
    Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling sphingomyelin synthase 1 driven reaction at the Golgi apparatus can explain data by inclusion of a positive feedback mechanism.
    Thomaseth C; Weber P; Hamm T; Kashima K; Radde N
    J Theor Biol; 2013 Nov; 337():174-80. PubMed ID: 24001971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
    Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells.
    Jin ZX; Huang CR; Dong L; Goda S; Kawanami T; Sawaki T; Sakai T; Tong XP; Masaki Y; Fukushima T; Tanaka M; Mimori T; Tojo H; Bloom ET; Okazaki T; Umehara H
    Int Immunol; 2008 Nov; 20(11):1427-37. PubMed ID: 18820264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of sphingomyelin synthase 1 gene expression at the transcriptional and translational levels in human tissues.
    Sudarkina OY; Filippenkov IB; Brodsky IB; Limborska SA; Dergunova LV
    Mol Cell Biochem; 2015 Aug; 406(1-2):91-9. PubMed ID: 25912551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C?
    Luberto C; Hannun YA
    J Biol Chem; 1998 Jun; 273(23):14550-9. PubMed ID: 9603970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.
    Mitsutake S; Zama K; Yokota H; Yoshida T; Tanaka M; Mitsui M; Ikawa M; Okabe M; Tanaka Y; Yamashita T; Takemoto H; Okazaki T; Watanabe K; Igarashi Y
    J Biol Chem; 2011 Aug; 286(32):28544-55. PubMed ID: 21669879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.